Physician profile
Katrina Mcdaniel
NPI 1952822082
$13,894.86
in general payments reported to CMS, 2019-2025
28 companies · $2,469 in 2025
The $2,469 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,552 · 2022: $2,404 · 2023: $3,092 · 2024: $4,377 · 2025: $2,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,686 · Consulting Fee: $850 · Education: $403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,685.54 |
| Consulting Fee | $850.00 |
| Education | $403.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,239.29 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Dermavant Sciences, INC. | $1,619.21 | 2023-2024 | Vtama |
| Ucb, INC. | $1,352.72 | 2021-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $1,315.28 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $1,145.79 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $932.33 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $801.06 | 2021-2025 | Otezla, Otezla |
| Leo Pharma INC. | $743.96 | 2022-2023 | Adbry |
| Sun Pharmaceutical Industries INC. | $644.02 | 2021-2025 | Blu-U |
| Novartis Pharmaceuticals Corporation | $556.30 | 2021-2023 | |
| Incyte Corporation | $397.82 | 2021-2024 | Opzelura |
| Galderma Laboratories, L.P. | $357.59 | 2021-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $333.76 | 2022-2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $284.98 | 2021-2025 | Jublia |
| Almirall LLC | $226.98 | 2022-2025 | Klisyri |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $198.43 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $172.91 | 2021-2025 | |
| Journey Medical Corporation | $125.84 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $88.30 | 2023 | Tremfya |
| Sanofi-Aventis U.S. LLC | $85.00 | 2025 | |
| Orthofix Medical, INC. | $66.19 | 2023 | Physio-Stim |
| Genzyme Corporation | $64.78 | 2021-2022 | |
| Organon LLC | $41.19 | 2025 | |
| Fidia Pharma USA INC. | $27.60 | 2025 | |
| Mayne Pharma Commercial LLC | $22.10 | 2025 | |
| Verrica Pharmaceuticals INC. | $18.17 | 2023 | Ycanth |
| Mission Pharmacal Company | $17.57 | 2021 | |
| Dermira, INC. | $15.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.